West on Lung Cancer
- 'How Could We Fail so Miserably?'
- Should We Be Doing Molecular Testing at the Time of Acquired Resistance?
- Linking Community and Academic Oncologists: Creating a New Model
- Is It Timing or Access? How Clinical Trials Game the System
- You Don't Need 800 Cable Channels (Or Tumor Genetic Mutations)
- At ESMO, New Data on Managing Long-term Immunotherapy Responders
- How the 2018 WCLC Data Change Lung Cancer Practice
- Jack West: Why CMS' Step Therapy Decision Is so Dangerous
- Is Upfront Combo Therapy Better Than the Sum of Its Parts?
- Does Immunotherapy Have a Role in EGFR-Mutant Lung Cancer?
- In NSCLC, Immunotherapy Evolving to Become First-Line Treatment
- The Best Ways to Dispel Patients' 'Cancer Myths' in Clinical Practice
- ASCO Data Establish Chemo-IO as Mainstay Frontline for NSCLC
- Tumor Mutation Burden as Biomarker: All-Systems-Go or Too Early?
- When Online Information Is the 'Third Party in the Exam Room'
- Which Patients With CNS Metastases Can Avoid Radiation?
- Dealing With Data Overload in Oncology
- Time to 'Rethink' Immunotherapy for Molecularly Driven NSCLC
- Trial 'Desperately Needed' to Sequence Immunotherapy and Chemo in Lung Cancer
- KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC